Combination effect of cold atmospheric plasma with green synthesized zero-valent iron nanoparticles in the treatment of melanoma cancer model.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
01
2022
accepted:
29
11
2022
entrez:
19
12
2022
pubmed:
20
12
2022
medline:
22
12
2022
Statut:
epublish
Résumé
Green synthesized zero-valent iron nanoparticles (nZVI) have high potential in cancer therapy. Cold atmospheric plasma (CAP) is also an emerging biomedical technique that has great potential to cure cancer. Therefore, the combined effect of CAP and nZVI might be promising in treatment of cancer. In this study, we evaluated the combined effect of CAP and nZVI on the metabolic activity of the surviving cells and induction of apoptosis in malignant melanoma in comparison with normal cells. Therefore, the effect of various time exposure of CAP radiation, different doses of nZVI, and the combined effect of CAP and nZVI were evaluated on the viability of malignant melanoma cells (B16-F10) and normal fibroblast cells (L929) at 24 h after treatment using MTT assay. Then, the effect of appropriate doses of each treatment on apoptosis was evaluated by fluorescence microscopy and flow cytometry with Annexin/PI staining. In addition, the expression of BAX, BCL2 and Caspase 3 (CASP3) was also assayed. The results showed although the combined effect of CAP and nZVI significantly showed cytotoxic effects and apoptotic activity on cancer cells, this treatment had no more effective compared to CAP or nZVI alone. In addition, evaluation of gene expression showed that combination therapy didn't improve expression of apoptotic genes in comparison with CAP or nZVI. In conclusion, combined treatment of CAP and nZVI does not seem to be able to improve the effect of monotherapy of CAP or nZVI. It may be due to the resistance of cancer cells to high ROS uptake or the accumulation of saturated ROS in cells, which prevents the intensification of apoptosis.
Identifiants
pubmed: 36534669
doi: 10.1371/journal.pone.0279120
pii: PONE-D-22-02370
pmc: PMC9762585
doi:
Substances chimiques
Iron
E1UOL152H7
Reactive Oxygen Species
0
Plasma Gases
0
Water Pollutants, Chemical
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0279120Informations de copyright
Copyright: © 2022 Yazdani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Biochem Biophys Res Commun. 2014 Aug 8;450(4):1266-71
pubmed: 24996177
Onco Targets Ther. 2016 Sep 28;9:5911-5917
pubmed: 27729800
J Cell Mol Med. 2016 Sep;20(9):1737-48
pubmed: 27256594
Free Radic Res. 2017 Mar;51(3):306-315
pubmed: 28325093
Oncol Lett. 2020 Jan;19(1):283-290
pubmed: 31897140
Int J Nanomedicine. 2018 Dec 28;14:243-256
pubmed: 30643404
Cancer Res. 2002 Apr 1;62(7):2098-103
pubmed: 11929831
Sci Rep. 2016 Jul 01;6:29098
pubmed: 27364563
Oncoimmunology. 2020 Dec 29;10(1):1859731
pubmed: 33457077
Biochim Biophys Acta. 2014 May;1840(5):1596-604
pubmed: 24060746
Nanomedicine. 2021 Aug;36:102436
pubmed: 34153528
Free Radic Biol Med. 2002 Dec 1;33(11):1440-50
pubmed: 12446201
J Exp Bot. 2000 Dec;51(353):2053-66
pubmed: 11141179
ACS Omega. 2021 Nov 23;6(48):32730-32738
pubmed: 34901621
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Oncol Rep. 2020 May;43(5):1683-1691
pubmed: 32323810
Sci Rep. 2016 Jul 08;6:29247
pubmed: 27386761
PLoS One. 2013 Nov 12;8(11):e79325
pubmed: 24265766
Pharmaceutics. 2022 Jan 02;14(1):
pubmed: 35056996
Nutr Cancer. 2020;72(4):708-721
pubmed: 31335223
PLoS One. 2013 Sep 11;8(9):e73741
pubmed: 24040051
Angew Chem Int Ed Engl. 2016 Feb 5;55(6):2101-6
pubmed: 26836344
Biomater Sci. 2019 Mar 26;7(4):1311-1322
pubmed: 30734774
J Invest Dermatol. 2001 Aug;117(2):333-40
pubmed: 11511312
Eur J Pharm Sci. 2019 Sep 1;137:105002
pubmed: 31302215
Sci Rep. 2016 Feb 26;6:21974
pubmed: 26917087
Environ Sci Technol. 2016 Jul 19;50(14):7290-304
pubmed: 27331413
Sci Rep. 2019 Oct 2;9(1):14210
pubmed: 31578342
Biomolecules. 2020 Jul 08;10(7):
pubmed: 32650505
Drug Resist Updat. 2004 Apr;7(2):97-110
pubmed: 15158766
Exp Dermatol. 2013 Apr;22(4):284-9
pubmed: 23528215
Turk J Biol. 2019 Jun 13;43(3):209-223
pubmed: 31320819
Cell Death Discov. 2020 Sep 10;6:83
pubmed: 32963811
Biochim Biophys Acta Mol Cell Res. 2019 Dec;1866(12):118536
pubmed: 31465809
Annu Rev Physiol. 1998;60:619-42
pubmed: 9558479
J Eur Acad Dermatol Venereol. 2011 Jan;25(1):1-11
pubmed: 20497290
Cancers (Basel). 2019 Sep 01;11(9):
pubmed: 31480642
Biochem Pharmacol. 2003 Oct 15;66(8):1527-35
pubmed: 14555231
Curr Oncol Rep. 2018 Sep 24;20(11):87
pubmed: 30250984
Cell Commun Signal. 2019 May 24;17(1):52
pubmed: 31126298
RSC Adv. 2018 Jul 20;8(46):26144-26155
pubmed: 35541956
Methods Mol Biol. 2011;731:237-45
pubmed: 21516412
PLoS One. 2014 Jan 21;9(1):e86173
pubmed: 24465942
FASEB J. 2007 Dec;21(14):3777-85
pubmed: 17625071
Cancer Biol Ther. 2012 Nov;13(13):1299-306
pubmed: 22895073
Arch Biochem Biophys. 2016 Sep 1;605:102-8
pubmed: 26820218
Front Immunol. 2021 Jun 09;12:693709
pubmed: 34177955
Environ Sci Technol. 2009 Jun 15;43(12):4555-60
pubmed: 19603676
Free Radic Biol Med. 2019 Jan;130:71-81
pubmed: 30342190
J Cell Commun Signal. 2017 Mar;11(1):97-104
pubmed: 28120184
Biomed Res Int. 2021 Nov 16;2021:1969863
pubmed: 34825002
Nat Biotechnol. 2007 Oct;25(10):1165-70
pubmed: 17891134
PLoS One. 2013 Aug 27;8(8):e73665
pubmed: 24013954
Oncotarget. 2017 Feb 28;8(9):15977-15995
pubmed: 27845910
Sci Rep. 2012;2:636
pubmed: 22957140
Biomed Pharmacother. 2019 Sep;117:109115
pubmed: 31220743
ChemSusChem. 2020 Jul 7;13(13):3288-3305
pubmed: 32357282